Market Overview

IntriCon Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares


IntriCon Corporation (NASDAQ:IIN), a designer, developer,
manufacturer and distributor of body-worn devices, today announced the
completion of its previously announced underwritten public offering of
1,725,000 shares of its common stock, including 225,000 shares sold
pursuant to the exercise in full of the underwriters' option to purchase
additional shares. All shares in the offering were sold by IntriCon at a
price to the public of $55.00 per share. Net proceeds from the offering,
including pursuant to the option exercise, after deducting underwriting
discounts and commissions and estimated offering expenses, are expected
to be approximately $88.9 million.

IntriCon intends to use these net proceeds to repay debt, to fund
capital expenditures, to repurchase and retire 500,000 shares of its
common stock from certain of its directors and officers at a price equal
to the net proceeds per share that IntriCon received from the offering,
before expenses, and for working capital and other general corporate

Stifel acted as sole book-running manager of the offering. B. Riley FBR
and Dougherty & Company LLC acted as co-managers of the offering.

The shares were issued pursuant to a shelf registration statement on
Form S-3 previously filed with and declared effective by the Securities
and Exchange Commission (the "SEC"). A final prospectus supplement
relating to this offering has been filed with the SEC. Copies of the
final prospectus supplement and the accompanying base prospectus may be
obtained from Stifel, Nicolaus & Company, Incorporated, Attention:
Syndicate, One Montgomery Street, Suite 3700, San Francisco, California
94104, by telephone at (415) 364-2720 or by email at
Electronic copies of the final prospectus supplement and accompanying
base prospectus are also available on the website of the SEC at

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the shares described herein or any other
securities, nor shall there be any sale of these securities in any state
or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities
laws of any such state or other jurisdiction. The offering may be made
only by means of a prospectus supplement and the accompanying base

About IntriCon Corporation

Headquartered in Arden Hills, Minn., IntriCon Corporation designs,
develops and manufactures miniature and micro-miniature body-worn
devices. These advanced products help medical, healthcare and
professional communications companies meet the rising demand for
smaller, more intelligent and better-connected devices. IntriCon has
facilities in the United States, Asia, the United Kingdom and Europe.
The company's common stock trades under the symbol "IIN" on the NASDAQ
Global Market. For more information about IntriCon, visit

Forward-Looking Statements

Statements made in this release and in IntriCon's other public filings
and releases that are not historical facts or that include
forward-looking terminology, including IntriCon's anticipated use of
proceeds from the offering, are "forward-looking statements" within the
meaning of the Securities Exchange Act of 1934, as amended. These
forward-looking statements may be affected by known and unknown risks,
uncertainties and other factors that are beyond IntriCon's control,
including the risks and uncertainties associated with IntriCon's actual
offering expenses, as well as risks and uncertainties inherent in
IntriCon's business, and may cause IntriCon's actual results,
performance or achievements to differ materially from the results,
performance and achievements expressed or implied in the forward-looking
statements. These risks, uncertainties and other factors are detailed
from time to time in the company's filings with the Securities and
Exchange Commission, including the Annual Report on Form 10-K for the
year ended December 31, 2017, and in the final prospectus supplement
related to the public offering, each available on the SEC's web site at
The company disclaims any intent or obligation to publicly update or
revise any forward-looking statements, regardless of whether new
information becomes available, future developments occur or otherwise.

View Comments and Join the Discussion!